Rationale for Intravenous Gamma-Globulin Therapy of Persistent Lymphotropic Viral Infections
Considerable clinical improvements reported in post-zoster neuralgia, X-linked lymphoproliferative syndrome, ARC or AIDS, autoimmune diseases as well as in chronic inflammatory disorders, following the administration of polyvalent intravenous immunoglobulin G (IVIG) (1), precipitated the idea to reconsider the rationale for IVIG therapy. Apparent therapeutic effects of IVIG can be subdivided into: A) substitution, B) modulation of cytokine release, and C) immunomodu-lation by idiotype-anti-idiotype (Id-aid) interactions. A) Substitution by IVIG can satisfy many of individual needs by substitution of the whole repertoire of the IgG class or of a single subclass in primary or secondary immunodeficiendes or by substitution of selective antibody deficiencies by clonal antibodies in otherwise immune competent patients. Substitution mediates antigen-directed actions as well as effector functions.
KeywordsChronic Inflammatory Disorder Peritoneal Exudate Cell Coagulation Factor Viii Immune Competent Patient Rabbit Peritoneal
- 1.B. Perret, C. Baumgartner, Vox Sang. in pressGoogle Scholar
- 3.M. Iwata, R. Shimozato, H. Tokiwa, E. Tsubura, In: Clinical use of intravenous immunoglobulin, A. Morell, U.E. Nydegger, Eds. (Academic Press, London, 1986) pp 327–338Google Scholar
- 4.Y. Sultan, M.D. Kazatchkine, P. Maisonneuve, U.E. Nydegger, Lancet II 765 (1984)Google Scholar